Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRO: Ofatumumab in Early-Stage Follicular Lymphoma
NCT02710643Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2014
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ofatumumab in follicular lymphoma (FL) (3 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Bcl-2 negativization after Ofatumumab at 4 years. Started Oct 2014; status: completed.
02
Drugs
ofatumumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02710643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710643.